SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Jul 27, 2006
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: July 27, 2006 · CIK: 0001130166 · Accession: 0000950136-06-006073
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-50626
Referenced dates: June 30, 2006
Letter
July 27, 2006 VIA EDGAR AND FEDEX ------------------- Amy C. Bruckner, Staff Accountant Division of Corporation Finance Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549
RE: CYCLACEL PHARMACEUTICALS, INC. ITEM 4.02(A) FORM 8-K FILED JUNE 29, 2006 FILED MARCH 1, 2006 FILE NO. 000-50626
Dear Ms. Bruckner:
On behalf of Cyclacel Pharmaceuticals, Inc. (the "Company"), we respond as follows to the Staff's legal comments dated June 30, 2006 relating to the above-captioned Form 8-K. Please note that for the Staff's convenience, we have recited each of the Staff's comments and provided our response to each comment immediately thereafter.
Item 4.02(a) Form 8-K filed June 29, 2006 -----------------------------------------
1. Please revise your disclosure and tell us when you intend to file the amendments to your Form 10-Q filed May 16, 2006 and your Form 8-K/A filed May 27, 2006.
ON JULY 7, 2006, CYCLACEL FILED AN AMENDED FORM 10-Q AND AN AMENDED FORM 8-K/A.
2. Please revise your disclosure to specify whether you have reconsidered, in accordance with item 307 of Regulaiton S-K, the adequacy of your previous assertion in your March 31, 2006 Form 10-Q regarding your disclosure controls and procedures, particularly in light of the material error and issue that you have described.
WE HAVE AMENDED THE TEXT IN ACCORDANCE WITH THE STAFF'S REQUEST REGARDING THE ADEQUACY OF CYCLACEL'S DISCLOSURE CONTROLS AND PROCEDURES. PLEASE SEE THE AMENDED FILINGS.
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
Amy C. Bruckner, Staff Accountant Securities and Exchange Commission July 27, 2006 Page 2
Closing Comments ---------------- At the request of the Staff, the Company acknowledges that (i) the Company is responsible for the adequacy and accuracy of the disclosure in the filing; (ii) Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and (iii) it may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please do not hesitate to contact me directly should you require any further information with respect to this filing or any future filings with respect to the Company.
Sincerely,
/s/ Todd E. Mason
-----------------
Show Raw Text
CORRESP
1
filename1.htm
[MINTZ LEVIN LOGO OMITTED] Chrysler Center
666 Third Avenue
New York, NY 10017
TODD E. MASON | 212 692 6731 | tmason@mintz.com 212-935-3000
212-983-3115 fax
www.mintz.com
July 27, 2006
VIA EDGAR AND FEDEX
-------------------
Amy C. Bruckner, Staff Accountant
Division of Corporation Finance
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, DC 20549
RE: CYCLACEL PHARMACEUTICALS, INC.
ITEM 4.02(A) FORM 8-K FILED JUNE 29, 2006
FILED MARCH 1, 2006
FILE NO. 000-50626
Dear Ms. Bruckner:
On behalf of Cyclacel Pharmaceuticals, Inc. (the "Company"), we
respond as follows to the Staff's legal comments dated June 30, 2006 relating to
the above-captioned Form 8-K. Please note that for the Staff's convenience, we
have recited each of the Staff's comments and provided our response to each
comment immediately thereafter.
Item 4.02(a) Form 8-K filed June 29, 2006
-----------------------------------------
1. Please revise your disclosure and tell us when you intend to file the
amendments to your Form 10-Q filed May 16, 2006 and your Form 8-K/A
filed May 27, 2006.
ON JULY 7, 2006, CYCLACEL FILED AN AMENDED FORM 10-Q AND AN AMENDED
FORM 8-K/A.
2. Please revise your disclosure to specify whether you have reconsidered,
in accordance with item 307 of Regulaiton S-K, the adequacy of your
previous assertion in your March 31, 2006 Form 10-Q regarding your
disclosure controls and procedures, particularly in light of the
material error and issue that you have described.
WE HAVE AMENDED THE TEXT IN ACCORDANCE WITH THE STAFF'S REQUEST
REGARDING THE ADEQUACY OF CYCLACEL'S DISCLOSURE CONTROLS AND
PROCEDURES. PLEASE SEE THE AMENDED FILINGS.
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
Amy C. Bruckner, Staff Accountant
Securities and Exchange Commission
July 27, 2006
Page 2
Closing Comments
----------------
At the request of the Staff, the Company acknowledges that (i) the
Company is responsible for the adequacy and accuracy of the disclosure
in the filing; (ii) Staff comments or changes to disclosure in
response to Staff comments do not foreclose the Commission from taking
any action with respect to the filing; and (iii) it may not assert
Staff comments as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the
United States.
Please do not hesitate to contact me directly should you require any
further information with respect to this filing or any future filings
with respect to the Company.
Sincerely,
/s/ Todd E. Mason
-----------------
Todd E. Mason
cc: Paul McBarron
Cyclacel Pharmaceuticals, Inc.